Show simple item record

dc.contributorUniversitat Ramon Llull. Facultat de Ciències de la Salut Blanquerna
dc.contributor.authorBernat Peguera, Adrià
dc.contributor.authorTrigueros Peña, Macedonia
dc.contributor.authorFerrando Díez, Angelica
dc.contributor.authorIbáñez, Cristina
dc.contributor.authorBystrup, Sara
dc.contributor.authorMartínez-Cardús, Anna
dc.contributor.authorMargelí, Mireia
dc.contributor.authorMartínez-Balibrea, Eva
dc.date.accessioned2024-03-08T19:22:39Z
dc.date.available2024-03-08T19:22:39Z
dc.date.created2021-11
dc.date.issued2022-01
dc.identifier.urihttp://hdl.handle.net/20.500.14342/3990
dc.description.abstractAfter the expiration of trastuzumab data exclusivity, biosimilar drugs were approved by regulatory agencies; among them, CT-P6 which was approved for the treatment of HER2-positive early- and advanced-breast cancer (BC) in 2018. Yet, reference trastuzumab (RTZ) is often combined with pertuzumab in early BC (EBC) patients treated with chemotherapy as it significantly improves the pathological complete response rate. Unfortunately, scarce preclinical and clinical data exists about the combination of CT-P6, pertuzumab and chemotherapy. Therefore, our aim was to study in vitro and in a retrospective cohort of EBC patients, whether CT-P6 was equivalent to RTZ when combined with pertuzumab with or without taxanes. In BT-474 and SKBR3 HER2þ cells we found that CT-P6 alone or in combination with pertuzumab had the same negative effect on cell proliferation, colony formation and HER2 downregulation as well as downstream activation, as RTZ. Adding paclitaxel to these treatments increased their effectivity to a similar extent. In HER2 1þ neuregulin-secreting MB-MDA-175 cells, combinations of CT-P6 or RTZ with pertuzumab were also effective, and mainly dependent on HER3:HER2 heterodimerization. In a retrospective cohort of 44 EBC HER2þ patients treated with neoadjuvant RTZ or CT-P6 in combination with pertuzumab and chemotherapy, we found no differences in efficacy or in adverse events. Moreover, the costs of CT-P6-based treatments were reduced by 1474.07 V/patient. All together we provide pre-clinical and clinical evidence of the equivalence of CT-P6 in combination with pertuzumab and chemotherapy and suggest studying these combinations also in HER2 low/negative BC patients.ca
dc.format.extent9 p.ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofThe Breast, 2022, 62: 1-9ca
dc.rights© L'autor/aca
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.otherMama -- Càncerca
dc.subject.otherCàncer de mama HER2-positiuca
dc.subject.otherBiosimilarca
dc.subject.otherTrastuzumabca
dc.subject.otherPertuzumabca
dc.subject.otherTaxanesca
dc.subject.otherCT-P6ca
dc.subject.otherMedicaments -- Administracióca
dc.titleEfficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: preclinical and real-life clinical dataca
dc.typeinfo:eu-repo/semantics/articleca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc615ca
dc.subject.udc616ca
dc.identifier.doihttps://doi.org/10.1016/j.breast.2022.01.007ca
dc.relation.projectIDinfo:eu-repo/grantAgreement/SUR del DEC/2017-SGR-1705ca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

© L'autor/a
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint